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Abstract 22 
A simple and selective ultrahigh-performance liquid chromatographic-Orbitrap mass 23 
spectrometric (UHPLC-HR-MS) method was developed and validated for the simultaneous 24 
detection and quantification of short-chain fatty acids (SCFAs) such as acetic, propionic, 25 
butyric, isobutyric, valeric, isovaleric, 2-methyl-butyric (IS) and lactic, pyruvic and succinic 26 
acid in human faecal samples. A simple extraction procedure with 0.001 % formic acid in 27 
water was performed on 40 samples. The extracts were centrifuged and analyzed by UHPLC-28 
HR-MS on a sub-2 µm column using gradient elution; meanwhile, the same samples were 29 
analyzed by GC-FID and HPLC-UV as reference methods. The UHPLC-HR-MS method 30 
showed a recovery of 83-105 %, a repeatability of 2.2-8.3 % and an intermediate precision 31 
of 2.9-9.4 %. The LOD and LLOQ were in the range of 0.04-0.23 and 0.2-0.5 µg/ml, 32 
respectively. Regarding the SCFAs, statistical analysis showed a good correlation between 33 
the data obtained by UHPLC-HR-MS and those provided by GC-FID (p >0.05). On the 34 
contrary, the LC-UV data were not in agreement with those obtained by UHPLC-HR-MS 35 
determination (p <0.05).  To the best of our knowledge, this is the first method available for 36 
the simultaneous extraction and quantification of SCFAs, lactic, pyruvic and succinic in 37 
faecal samples by UHPLC-HR-MS.  38 
 39 
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1. Introduction 42 
The intestinal microbiota has been proposed as an additional organ of the human body that 43 
performs numerous functions, ranging from immunomodulation to improvement of nutrient 44 
bioavailability and competitive exclusion against potential detrimental microorganisms [1]. 45 
Therefore, the modification of the intestinal microbial ecosystem may potentially induce 46 
functional changes that could affect the health of the host with the consequent onset of 47 
pathologies. Irritable bowel syndrome (IBS) is one of the most common gastrointestinal 48 
disorders in the industrialized World [2]. The prevalence of IBS is approximately 10-15% 49 
[2]. The diagnosis is based on internationally accepted symptom-based criteria after 50 
exclusion of organic diseases [3]. Extensive research has been carried out to find valid and 51 
reliable biomarkers for IBS, but so far, none has been judged as satisfactory for the use in 52 
daily practice [4]. The association between IBS and gut microbiota has been demonstrated 53 
in several studies and efforts have been made to characterize the abnormal microbiota in 54 
patients with IBS [5]. The results seem inconsistent but some microbiota metabolites such 55 
as short-chain fatty acids (SCFAs), which have extensive immunological and regulatory 56 
functions, appear to be the link in the host-microbe interactions [6]. The relation between 57 
SCFAs and functional bowel disorders has not been extensively investigated, but 58 
immunological activation detected in subjects with IBS could be associated with the changes 59 
in SCFAs [7- 9]. Approximately 83% of SCFAs in the human colon is represented by butyric, 60 
acetic and propionic acid [10]. Their concentration in the intestinal lumen ranges from 60 to 61 
150 mmol/kg [11], and the acetate-propionate-butyrate balance is relatively constant, with a 62 
typical ratio of 60:25:10 [12]. Among these, butyrate appears to be a potential new IBS 63 
therapy [10, 13-14]. In order to isolate SCFAs and other organic acids from complex 64 
matrices such as faeces, several sample preparation procedures have been developed and 65 
applied including filtration [15], liquid-liquid [16] or solid-phase extraction [17]. The 66 
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determination of SCFAs in faecal samples is generally performed by gas chromatography in 67 
combination with flame-ionization [18] or MS detection without [19] or with derivatization 68 
to improve chromatographic behaviour or to increase molecular weight [20]. Alternatively, 69 
SCFA determination can be performed by capillary electrophoresis [21] and liquid 70 
chromatography coupled to refractive index [22-23], conductivity [24], electrochemical [15], 71 
spectrophotometric [25-26] or mass spectrometer [27] detector. More recently, Raposo and 72 
colleagues [23] published a multi-laboratory study regarding the quantitative determination 73 
of volatile fatty acids in aqueous matrix by GC-FID and HPLC coupled to conductivity, RI 74 
and UV. Short-chain fatty acids have no chromophore group, thus their detection occur only 75 
at short ultraviolet wavelengths (200-210 nm), and this can compromise method selectivity. 76 
To overcome this problem, several methods have been developed including derivatization 77 
of the organic acids with consequent formation of products absorbing at higher UV 78 
wavelengths [28]. This increases the specificity but also the time-consuming. 79 
The aim of this study was to develop a simple and cost-effective method based on UHPLC 80 
coupled to Orbitrap Mass Spectrometer (HR-MS) for the quantification of SCFAs (C2-C5) 81 
and other organic acids such as lactic, pyruvic and succinic in faecal samples. The selected 82 
analytes and their deprotonated ions are shown in Table 1. The increases specificity and 83 
sensitivity of HR-MS has allowed simplifying the sample preparation procedure permitting 84 
the routine use of the developed and validated UHPLC-HR-MS method. Moreover, the 85 
method was applied for the quantitative determination of SCFAs and organic acids in human 86 
faecal samples, and the observed outcomes were compared with those obtained by using LC-87 
UV and GC-FID assay method reported in literature. 88 
 89 
 90 
 91 
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2. Experimental 92 
2.1 Chemicals   93 
Analytical grade pyruvic (Pyr), lactic (LA), acetic (AA), succinic (SA), propionic (PA), 94 
methyl-malonic (MMA), butyric (BA), isobutyric (iBA), 2-methylbutyric (2-MBA, IS), 95 
valeric (VA), isovaleric (iVA), oxaloacetic (OxA) and acetoacetic (AcA) acid were used as 96 
standards (Sigma-Aldrich, Milan, Italy), and their purity was higher than 98%. Acetonitrile, 97 
methanol and formic acid LC-MS grade were from Sigma. Water was obtained from a MilliQ 98 
apparatus (Millipore, Milford, MA). Human faecal samples (n=40) were a kind gift of prof. 99 
Guglielmetti (University of Milan, DeFENS). 100 
 101 
2.2. Sample preparation 102 
Approximately 100 mg of faecal sample was suspended in 2 ml of a solution 0.001 % 103 
HCOOH in water containing 2-MBA (IS, 50 µmolar). After vortexing for 1 min, the 104 
suspension was centrifuged at 10,000-x g for 1 min, and the supernatant was collected into 105 
a 5 ml flask. The residue was treated with 2 ml of a solution 0.001 % HCOOH in water 106 
containing 2-MBA (50 µmolar), vortexed for 1 min and centrifuged at 10,000-x g for 1 min. 107 
The supernatant was pooled; the volume was adjusted to 5 ml with 0.001 % HCOOH in 108 
water containing 2-MBA (50 µmolar) and the solution stored at -20°C until analysis. 109 
 110 
2.3. UHPLC-HR-MS determination 111 
The analysis was carried out on an Acquity UHPLC separation module (Waters, Milford, 112 
MA, USA) coupled with a model Exactive Orbitrap MS through an HESI-II probe for 113 
electrospray ionization (Thermo Scientific, San Jose, CA, USA) set in negative ion mode. 114 
The ion source and interface conditions were: spray voltage -3.0 kV, capillary -27 V, tube 115 
lens -80 V, skimmer -16 V, sheath gas flow-rate 35, auxiliary gas flow-rate 10, heater and 116 
capillary temperature 120 and 320 °C, respectively. A 1.8 m HSS T3 column (150x2.1 mm, 117 
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Waters) was used for separation at a flow-rate of 0.2 ml/min. The eluents were 0.001% 118 
HCOOH in MilliQ-treated water (solvent A) and CH3OH:CH3CN (1:1, v/v, solvent B). Five 119 
µl of the sample were separated by the UHPLC using the following elution gradient: 0% B 120 
for 4 min, 0-15% B in 6 min, 15-20 % B in 5 min, 20 % for 13 min and then return to initial 121 
conditions in 1 min. The column and samples were kept at 30 and 10 °C, respectively. The 122 
UHPLC eluate was analyzed in full scan MS in the range (m/z)- 50-150 u. The resolution, 123 
AGC target, maximum ion injection time and mass tolerance were 50 K, 1E6, 100 ms and 2 124 
ppm, respectively. The ion with m/z 91.0038 and 112.9858 u, corresponding to the formic 125 
acid dimer [2M-H]- and formic acid dimer Na adduct [2M+Na-2H]-, respectively, has been 126 
used as lock mass. The MS data were processed using Xcalibur software (Thermo 127 
Scientific). Lactic, AA, PA, BA, iBA, VA and iVA mother solutions (1mg/ml) were 128 
prepared by dissolving 0.1 ml of standard in 100 ml of water. Mother solution for Pyr, OxA, 129 
AcA, MMA and SA was prepared by dissolving 20 mg of standard powder in 20 ml of water. 130 
The working solutions in 0.001% formic acid were prepared in the range of 1.9-255 µmolar 131 
for PA, BA, iBA, iVA, VA, 4.2-315 µmolar for LA, AA, SA, 5.7-51.1 and 51.1-214.8 132 
µmolar for Pyr  (Table 2).  133 
 134 
2.4 Method validation 135 
2.4.1 Sensitivity, selectivity and Matrix Effect (ME) 136 
Calibration curves were constructed for each standard at six concentration levels and 2-MBA 137 
was used as an internal standard to correct for the loss of analytes during sample preparation. 138 
Six independent determinations were performed at each concentration and regression 139 
analysis was employed to determine the linearity of the calibration graphs. LLOQ was 140 
defined by the lowest injected inter-day concentration whose RSD% resulted to be lower 141 
than 20 % [29]. LOD was defined by the lowest concentration the assay can differentiate 142 
  7 
 
from background levels (S/N ratio > 5). Selectivity was evaluated by comparing the retention 143 
time and accurate mass of each analytes in faecal samples, standard solutions and spiked 144 
faecal samples. The possible interference from other organic acids such as MMA, OxA and 145 
AcA was also evaluated. Matrix effect (ME) was evaluated as described by Garcia-Villalba 146 
et al. [19]. Briefly, the response of the standards in 0.001 % HCOOH (0.5-21, µg/ml, n=6) 147 
was compared with that of the same compounds in faecal extract spiked with standards at 148 
the same concentration levels. Unspiked samples were also analyzed to determine the initial 149 
amount of each compound present in the sample. All peak areas were normalized by the area 150 
of the IS and the percentage ME was calculated as follows: %ME = [(A-B)/C] x 100 151 
Where, A: Area of the analytes in the post extraction spiked sample, B: Area in the unspiked 152 
sample, C: Area in 0.001 % formic acid solution. The ratio of the calibration graph slopes 153 
have also been used for the evaluation of the %ME using the following equation: %ME = 154 
(m1/m2) x 100. Where, m1: slope of the analytes in the post-extraction sample, m2: slope 155 
of the analytes in 0.001 % HCOOH. 156 
 157 
2.4.2 Accuracy 158 
In order to optimize the extraction conditions, different quantities of faeces, from 20 to 200 159 
mg, were suspended in 4 ml of a solution 0.001 % HCOOH in water containing IS (5 µg/ml). 160 
The suspension was vortexed for 1 min, centrifuged at 10,000-x g for 1 min, and the 161 
supernatant was moved to a flask and the volume set to 5 ml by a solution of 0.001 % 162 
HCOOH in water containing IS (5 µg/ml). The accuracy of the procedure was determined 163 
by a recovery test according to the published method [30]. Briefly, three faecal samples were 164 
spiked with different amounts of the analytes (2-10-20 µg). The spiked samples were 165 
extracted under optimised conditions, and the recovery rates calculated. Each sample was 166 
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extracted and analysed in triplicate. Every ten analysis, a standard solution was injected to 167 
verify the mass spectrometer response. 168 
 169 
2.4.3. Precision 170 
Intra- and inter-day precision of the assay were verified by analyzing the same faecal sample 171 
four times for five consecutive days. Precision was confirmed by evaluating standard 172 
deviations of the amounts and of retention times. 173 
 174 
2.4.4. Robustness study 175 
Two analysts evaluating the amounts of the analytes in a faecal sample estimated the 176 
ruggedness of the proposed UHPLC-HR-MS method. Each analyst performed twelve tests 177 
and standard and extract solutions were injected in triplicate. Robustness was estimated by 178 
varying several chromatographic conditions such as flow-rate -0.05,+0.2 ml/min, column 179 
temperature ±5 ◦C, organic strength 0-0.1 % HCOOH in water, pH 3-7, capillary voltage ±3 180 
V, skimmer ±2 V and tube lens ±5 V. Data were analyzed by Wilcoxon test considering 181 
significant a level of p>0.05. 182 
 183 
2.4.5. Stability studies 184 
The faecal and standards solutions were stored at -20 °C and 4 °C, respectively, and their 185 
stability evaluated up to 30 days. The 24-h stabilities of all analytes were measured in three 186 
faecal extracts and standard solutions at the UHPLC-HR-MS autosampler temperature of 10 187 
°C.  188 
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2.5. Quantitative analysis of SCFAs and organic acids by reference methods    189 
 190 
2.5.1. LC-UV analysis 191 
Quantification of SCFAs in faecal samples was carried out using external calibration 192 
standard curves method. Six levels of concentration ranging from 0.3 to 10.4 mg/ml were 193 
used. 194 
 195 
2.5.2. GC-FID analysis 196 
Faecal samples were extracted and analysed according to Zhao et al. [18]. Calibration 197 
solutions were in the range 0.1-5.2 mg/ml.  198 
 199 
2.6. Statistical analysis 200 
Wilcoxon and t test was performed by Statistica 10 software (Statsoft Inc., Tulsa, OK, USA) 201 
and other calculations were carried out using Excel software. Analytes amount were 202 
expressed as µmoles/100 mg of wet faeces. 203 
204 
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3. Results and discussion 205 
 206 
3.1 Optimization of UHPLC-MS conditions   207 
In a preliminary phase, different sub-2m columns (150x2.1 mm, C18 and PFP) were tested 208 
in order to optimise the condition of separation. The columns tested were from Waters (BEH, 209 
BEH Shield, HSS, HSS-SB and HSS-T3), Phenomenex (Kinetex, Kinetex-XB and Kinetex 210 
PFP) and Thermo (Hypersil Gold and Gold PFP). The separation efficiency and peak shape 211 
obtained through the C18 columns were better than the PFP columns and for the separation 212 
of SCFAs, pyruvic, lactic and succinic acid, the HSS T3 C18 column achieved the best 213 
performance. Regarding MS conditions, the determinations were carried out in negative ion 214 
mode, as the analytes signal was much higher than that in positive ion mode. For all the 215 
analytes, the MS analysis showed the presence of deprotonated molecular ion [M-H]-. 216 
Critically remarkable, for SA and MMA an ion with m/z of 72.0295 u, corresponding to [M-217 
CO2-H]
-, was present even at lower voltage. This indicates that these compounds could easily 218 
lose a carboxyl group giving PA (see Supplementary material 1). Consequently, 219 
chromatographic separation is mandatory to avoid an overestimation of the amount of PA in 220 
the faecal specimen. In the chromatographic conditions used, methylmalonic, SA and PA 221 
were well separated and their retention time was 6.1, 7.4 and 10.3 min, respectively. 222 
Oxaloacetic acid also easily lost a carboxyl group giving Pyr (see Supplementary material 223 
1). Thus, also in this case the chromatographic separation was mandatory. Pyruvic and OxA 224 
had retention time of 4.5 and 9.1 min, respectively. Acetoacetic acid did not produce 225 
interfering. Therefore, the obtained data seem to suggest that some dicarboxylic acids, losing 226 
spontaneously a carboxyl group, may interfere with the quantification of some SCFAs, LA 227 
and Pyr. 228 
 229 
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3.2 Sample preparation for UHPLC-HR-MS analysis 230 
Two subsequent extractions were preliminarily applied to extract the analytes present in the 231 
faecal samples. The extracted amount following the first and second extraction was 97.1±1.1 232 
and 2.9±0.4 %, respectively. Thus, for the routine analysis one extraction (5 mL) was 233 
performed. The extraction procedure was linear in the range of 20-200 mg of faeces, thus 234 
about 100 mg were used for the routine analysis of SCFAs and organic acids. When this 235 
amount was not available, the extraction was carried out in order to obtain a suspension 236 
containing 20 mg faeces/ml.  237 
 238 
3.3 Method validation 239 
3.3.1 Sensitivity, selectivity and matrix effect 240 
The calibration curves showed a coefficient of determination (R2) ranging from 0.9981 to 241 
0.9992. Analytes had a narrow linear range (approximately 0.032-0.185 mMolar) which 242 
encompassed the amounts present in most samples. Only for some samples containing high 243 
concentrations of acetic acid was necessary a 10-fold dilution.  244 
Selectivity was confirmed by comparing the retention time of each analyte in standard 245 
solution with those of faecal extracts and extracts spiked with standards. The %RSD of the 246 
retention times was lower than 0.9%. Peak identity was also verified evaluating the [M-H]- 247 
with a tolerance of 2 ppm. The method of standard addition was used to correct the loss of 248 
analytes during sample preparation and their quantification performed by external 249 
calibration.  250 
 Percentage ME values calculated with peak area and calibration slopes method were in the 251 
range of 93-105 % and 0.93-1.05, respectively. Thus, the interference of the matrix with the 252 
analytes signal in the faecal samples was not reliable.  253 
 254 
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3.3.2 Accuracy 255 
The percentage mean recovery values of the extraction for the analytes from spiked faecal 256 
samples was in the range of 83-105 % and the %RSD was lower than 8.7 (Table 2).  257 
 258 
3.3.3 Precision 259 
The intra- (n=4) and inter-day precision (n=5) was evaluated analyzing in triplicate the 260 
spiked samples. Repeatability and intermediate precision resulted to be in the range of 2.2-261 
8.3 % and 2.9- 9.4 %, respectively (Table 2).   262 
 263 
3.3.4 Robustness study  264 
Regarding robustness, slight variations in pH and column temperature do not change the 265 
peak shape and resolution, and moderate variations in capillary (±3V), skimmer and tube 266 
lens voltage did not influence significantly (p>0.5) the quantification of the analytes. On the 267 
contrary, increments of the flow-rate or the percentage of formic acid in the eluent caused a 268 
drastic decrease of the peak relative to AA and PA and a more modest reduction of the signal 269 
related to other SCFAs. In particular, an increase of 0.003 % in the percentage of formic acid 270 
caused a reduction of the peak intensity for AA and PA of 70 and 50 %, respectively; while 271 
for BA and iBA the reduction was about 25 %. To achieve a significant reduction of the 272 
peaks of VA and iVA, formic acid concentration was increased up to 0.005 %. For Pyr, LA 273 
and SA, the augment of the percentage of formic acid in the eluent caused an improvement 274 
of the shape of the peak and an increase of the response. A reduction in the percentage of 275 
formic acid in the eluent or the replacement with water caused a broadening of the peak 276 
shape and a decrease of its intensity. Regarding flow-rate, an increase caused a loss of 277 
resolution for AA, Pyr and LA, which resulted not base-separated and the intensity of the 278 
signal relative to AA and PA decreased up to 50 and 30 %, respectively. Thus, the proposed 279 
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method was found to be robust and rugged but particular attention should be paid to the 280 
formic acid percentage in the eluent.  281 
 282 
3.3.5 Stability studies 283 
The mean of AA and other analytes recovered from the faecal extracts stored at -20 C for 284 
up 30 days was 90 and 95 %, respectively. Standard solutions stored at -20 C for up 30 days 285 
showed a slight reduction of about 1.9 and 1.3 % for AA and other analytes, respectively.  286 
All the analytes in standard solutions and faecal extracts resulted stable in the autosampler 287 
at 10 C overnight (RSD<4.3 %).  288 
  289 
 3.4 Quantitative analysis of SCFAs, LA, SA and Pyr in human faecal samples by UHPLC-290 
HR-MS, GC-FID and LC-UV 291 
The efficiency of the proposed UHPLC-HR-MS method was tested by analyzing the levels 292 
of SCFAs, LA, SA and Pyr in faecal samples from humans. Figure 1 shows a typical 293 
UHPLC-HR-MS chromatogram of a faecal extract. The separation of all the analytes was 294 
completed within 30 min using an UHPLC column with a flow-rate of 0.2 ml/min, which 295 
was a balance between ionization and column performance. 296 
In addition, in some faecal extracts were found ions with m/z 89.0244 u, corresponding to 297 
LA, but with retention times higher than LA (Fig. 1, peak B and C). The peak B spectra 298 
showed also the presence of an abundant ion with m/z 161.0451 u, which formula brute 299 
(C6H9O5) corresponds to a dimer of the LA (error <3ppm). The peak C spectrum contains an 300 
unidentified ion with m/z 301.0543 u. The concentrations of the analytes were all within the 301 
linear range for all the samples analyzed and the results are shown in Table 3.   302 
In general, as might be expected, a high inter-individual variability in the content of faecal 303 
SCFAs was observed (RSD 33-100 %). The high variability in the levels of the SCFAs are 304 
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likely strongly regulated by many different factors such as diet, environment, microbiota 305 
composition and activity, gut transit time and health of the intestine [31-32]. 306 
Nevertheless, our data indicated that the most abundant SCFAs detected in the faecal 307 
samples were AA, PA and BA, representing approximately 48, 18 and 9 %, respectively, of 308 
the total SCFAs in human samples. These data, together with the content of iBA, VA and 309 
iVA, are in agreement with those reported in the literature [18-19, 33].   310 
Regarding the comparison with LC-UV and GC-FID method, the amounts of SCFAs did not 311 
match those given by the traditional LC-UV analysis (p<0.05, Supplementary material 2). 312 
Lacking chromophores, SCFAs and organic acids do not have a typical UV spectrum; for 313 
this reason, their identification in LC-UV was only based on time retention, which could 314 
easily overestimate the actual amount of such compounds in faecal sample.  315 
This could explain the high values of SCFAs in faeces reported by some authors who have 316 
carried out the measurement using LC-UV technique. In particular, some authors found 317 
about 10-fold higher stool SCFA levels [34] than others. On the contrary, the amounts of 318 
SCFAs obtained performing the analysis by HR-MS showed a good correlation with data 319 
obtained using GC-FID technique (p>0.05). Therefore, the two methods are comparable and 320 
the HR-MS technique can be applied for the simultaneous detection and quantification of 321 
volatile and non-volatile organic acids in human faecal samples. 322 
 323 
4. Conclusion 324 
To the best of our knowledge, this is the first validated UHPLC-HR-MS method for the 325 
simultaneous detection of AA, PA, BA, iBA, VA, iVA, LA, Pyr and SA in human faeces. 326 
The validation showed good results for recovery, repeatability, LOD, LOQ, linearity and 327 
stability. Moreover, the UHPLC coupled with an Orbitrap detector makes the method more 328 
sensitive and specific. The method was successfully applied to analyse the faecal samples 329 
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and an internal standard used to assess the loss of analytes during the extraction step. Being 330 
easy to use and offering satisfactory chromatographic performances, such procedures make 331 
these methods particularly suitable for the routine analysis of SCFAs and organic acids in 332 
faecal samples. 333 
 334 
Conflict of interest and funding sources  335 
The authors declare that they have no conflict of interest. 336 
This research did not receive any specific grant from funding agencies in the public, 337 
commercial, or not-for-profit sectors.   338 
  16 
 
References 339 
 340 
[1] O. Goulet, Potential role of the intestinal microbiota in programming health and disease, 341 
Nutr. Rev. 73 (2015) 32-40. 342 
 343 
[2] R.M. Lovell, A.C. Ford, Global prevalence of and risk factors for irritable bowel 344 
syndrome: a meta-analysis, Clin. Gastroenterol. Hepatol. 10 (2012) 712–21. 345 
 346 
[3] G.F. Longstreth, W.G. Thompson, W.D. Chey, L.A. Houghton, et al., Functional bowel 347 
disorders, Gastroenterology 130 (2006) 1480-91. 348 
 349 
[4] R. Sood, D.J. Gracie, G.R. Law, A.C. Ford, Systematic review with meta-analysis: the 350 
accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or 351 
psychological markers, Aliment. Pharmacol. Ther. 42 (2015) 491-503. 352 
 353 
[5] H.L. Dupont, Review article: evidence for the role of gut microbiota in irritable bowel 354 
syndrome and its potential influence on therapeutic targets, Aliment. Pharmacol. Ther. 355 
39 (2014) 1033-42. 356 
 357 
[6] J. Tan, C. McKenzie, M. Potamitis, A.N. Thorburn, et al., The role of short-chain fatty 358 
acids in health and disease, Adv. Immunol. 121 (2014) 91-119. 359 
 360 
[7] M.A. Vinolo, H.G. Rodrigues, R.T. Nachbar, R. Curi, Regulation of inflammation by 361 
short chain fatty acids, Nutrients 3 (2011) 858-76. 362 
 363 
[8] I. Ahmed, R. Greenwood, B.L. Costello, N.M. Ratcliffe, et al., An investigation of fecal 364 
volatile organic metabolites in irritable bowel syndrome, PLOS One 8 (2013) e58204. 365 
 366 
[9] P.G. Farup, K. Rudi, K. Hestad, Faecal short-chain fatty acids - a diagnostic biomarker 367 
for irritable bowel syndrome? BMC Gastroenterol. 16 (2016) 51.  368 
 369 
[10] A. Załęski, A. Banaszkiewicz, J. Walkowiak, Butyric acid in irritable bowel syndrome,  370 
Prz Gastroenterol. 8 (2013) 350-353. 371 
 372 
  17 
 
[11] D.L. Topping, P.M. Clifton, Short-chain fatty acids and human colonic function: roles 373 
of resistant starch and nonstarch polysaccharides, Physiol Rev. 81 (2001) 31-64. 374 
 375 
[12] W. Scheppach, P Bartram, A Richter, et al. Effect of short-chain fatty acids on the 376 
human colonic mucosa in vitro, J Parenter. Enteral Nutr. 16 (1992) 43-8. 377 
 378 
[13] T. Banasiewicz, E. Kaczmarek, J. Maik, et al., Quality of life and the clinical symptoms 379 
at the patients with irritable bowel syndrome treated complementary with protected 380 
sodium butyrate, Gastroenterol Prakt. 45 (2011) 45-53. 381 
 382 
[14] W. Tarnowski, K. Borycka-Kiciak, A. Kiciak, et al., Outcome of treatment with butyric 383 
acid in irritable bowel syndrome - preliminary report, Gastroenterol Prakt. 1 (2011) 43-384 
8. 385 
 386 
[15] A. Kotani,  Y. Miyaguchi, M. Kohama, T. Ohtsuka, et al., Determination  of short-chain 387 
fatty acids in rat and human feces by high-performance liquid chromatography with 388 
electrochemical detection, Anal. Sci. 25 (2009) 1007-1011. 389 
 390 
[16] T. Torii, K. Kanemitsu, T. Wada, S. Itoh, et al., Measurement  of short-chain fatty acids 391 
in human faeces using high-performance liquid chromatography: specimen  stability, 392 
Ann. Clin. Biochem. 47 (2010) 447-452. 393 
 394 
[17] L.J.I. Horspool, Q.A. McKellar, Determination of short-chain fatty acids in caecal liquor 395 
by ion exchange high performance liquid chromatography solid phase extraction, 396 
Biomed. Chromatogr. 5 (1991) 202-206.   397 
 398 
[18] G. Zhao, M. Nyman, J. Å. Jönsson, Rapid determination of short-chain fatty acids in 399 
colonic contents and faeces of humans and rats by acidified water-extraction and direct-400 
injection gas chromatography, Biomed. Chromatogr. 20 (2006) 674-682. 401 
 402 
[19] R. Garcıa-Villalba, J.A. Gimenez-Bastida, M.T. Garcıa-Conesa, F.A. Tomas-Barberan, 403 
et al., Alternative method for gas chromatography-mass spectrometry analysis of short-404 
chain fatty acids in faecal samples, J. Sep. Sci. 35 (2012) 1906-1913. 405 
 406 
  18 
 
[20] ]X. Zheng, Y. Qiu, W. Zhong, S. Baxter, et al., (2013)  A targeted metabolomic protocol 407 
for short-chain fatty acids and branched-chain amino acid, Metabolomics 9 (2013) 818–408 
827 409 
 410 
[21] C.W. Klampfl, W. Buchbergera, P.R. Haddadb, Determination of organic acids in food 411 
samples by capillary zone electrophoresis, J. Chromatogr. A 881 (2000) 357-364 412 
 413 
[22] K.  Manderson, M.  Pinart, K.M. Tuohy, W.E. Grace, et al., In vitro determination of 414 
prebiotic properties of oligosaccharides derived from an orange juice manufacturing by-415 
product stream, Appl. Environ. Microb. 71 (2005) 8383-8389. 416 
 417 
[23] F. Raposo, R. Borja, J.A. Cacho, J. Mumme, et al., Harmonization of the quantitative 418 
determination of volatile fatty acids profile in aqueous matrix samples by direct 419 
injection using gas chromatography and high-performance liquid chromatography 420 
techniques: Multi-laboratory validation study, J. Chromatogr. A. 1413 (2015) 94-106. 421 
 422 
[24] R. Widiastuti, P.R. Haddad, P.E. Jackson, Approaches to gradient elution in ion-423 
exclusion chromatography of carboxylic acids J. Chromatogr. A 602 (1992) 43-50. 424 
 425 
[25] N. Huda-Faujan, A.S. Abdulamir, A.B. Anas, O.M. Fatimah, et al., The impact of the 426 
level of the intestinal short chain fatty acids in inflammatory bowel disease patients 427 
versus healthy subjects, Open Biochem. J. 4 (2010) 53-58.  428 
 429 
[26] S. De Baerea, V. Eeckhautb, M. Steppeb, C. De Maesschalckb, et al., Development of 430 
a HPLC-UV method for the quantitative determination of four short-chain fatty acids 431 
and lactic acid produced by intestinal bacteria during in vitro fermentation, J. Pharm. 432 
Biom. Anal. 80 (2013) 107-115. 433 
 434 
[27] K.L. Ross, T.T. Tu, S. Smith, J.J. Dalluge, Profiling of organic acids during fermentation 435 
by ultraperformance liquid chromatography-tandem mass spectrometry, Anal. Chem. 436 
79 (2007) 4840-4844. 437 
 438 
  19 
 
[28] M. Czauderna, J. Kowalczyk, Lactic acid can be easily and precisely determined by 439 
reversed-phase high performance liquid chromatography with pre-column 440 
derivatization, J. Anim. Feed Sci.17 (2008) 268–279. 441 
 442 
[29] V.P. Shah, K.K. Midha, J.W. Findlay, H.H. Hill, et al., Bioanalytical method validation-443 
a revisit with a decade of progress, Pharm. Res. 17 (2000) 1551-1557. 444 
 445 
[30] B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng, Strategies for the assessment 446 
of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS, Anal. 447 
Chem. 75 (2003) 3019-3030. 448 
 449 
[31] D. Ríos-Covián, P. Ruas-Madiedo, A. Margolles, M. Gueimonde, et al., 450 
Intestinal Short Chain Fatty Acids and their link with diet and human health, Front. 451 
Microbiol. 7 (2016) 185. 452 
 453 
[32] G. den Besten, K. van Eunen, A.K. Groen, K. Venema, et al., The role of short-454 
chain fatty acids in the interplay between diet, gut microbiota, and host energy 455 
metabolism. J. Lipid Res. 54 (2013) 2325-40. 456 
 457 
[33] A.M. Henningsson, E.M.G.L. Nyman, I.M.E. Bjorck, Short-chain fatty acid content in 458 
the hindgut of rats fed various composite foods and commercial dietary fibre fractions 459 
from similar sources, J. Sci. Food Agric. 82 (2002) 385:393. 460 
 461 
[34] C. Ferrario, V. Taverniti, C. Milani, W. Fiore, et al., Modulation of fecal Clostridiales 462 
bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies 463 
among healthy adults, J. Nutr. 144 (2014) 1787-1796. 464 
465 
  20 
 
Legends to the figures 466 
 467 
Figure 1. Typical UHPLC-HR-MS chromatogram of a faecal extract sample.  468 
The extracted ions are: 1, Lactic (m/z)
-
 89.0244; 2, Pyruvic 87.0087; 3, Acetic 59.0138; 4, 469 
Succinic 117.0193; 5, Propionic 73.0295; 6, Butyric 87.0451; 7, isoButyric 87.0451; 8, 2-470 
methylButyric (IS) 101.0608; 9, isoValeric 101.0608; 10, Valeric acid 101.0608 u.  471 
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Table 1. Brute formula and characteristic deprotonated ions [M-H]- of SCFA, LA, Pyr and 472 
SA and possible interfering compounds.  473 
 474 
Analyte RT (min) Structure [M-H]- 
Acetic acid (AA) 4.8 CH3-COOH 59.0138 
Propionic acid (PA) 10.3 CH3-CH2-COOH 73.0295 
Butyric acid (BA) 15.8 CH3-CH2-CH2-COOH 87.0451 
isoButyric acid (iBA) 16.0 (CH3)2-CH-COOH 87.0451 
Valeric acid (VA) 26.8 CH3-CH2-CH2-CH2-COOH 101.0608 
isoValeric acid (iVA) 24.5 (CH3)2-CH-CH2-COOH 101.0608 
Lactic acid (LA) 4.3 CH3-CH(OH)-COOH 89.0244 
Pyruvic acid (Pyr) 4.5 CH3-C(O)-COOH 87.0087 
Succinic acid (SA) 7.4 HOOC-CH2-CH2-COOH 117.0193 
I.S. (2-MBA) 18.6 CH3-CH2-CH2-(CH3)-COOH 101.0608 
Possible interfering  Structure [M-H]- 
Acetoacetic acid (AcA) 8.1 CH3-C(O)-CH2-COOH 101.0244 
methyl-malonic acid (MMA) 6.1 HOOC-CH(CH3)-COOH 117.0193 
Oxaloacetic acid (OxA) 9.1 HOOC-C(O)-CH2-COOH 130.9985 
  475 
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Table 2. Limit of detection (LOD), linear range, accuracy and precision for the UHPLC-476 
HR-MS analysis of six SCFAs and three non-volatile organic acids in human faeces. 477 
Accuracy and precision were evaluated using faeces spiked with three different amounts of 478 
standard compounds.   479 
  External calibrationa Spiked faecal samples 
Analyte LOD  Range  LOQb 
Added 
µmoles 
Recovery 
(%) 
RSD 
(%) 
Intra-day 
RSD% 
(n=4) 
Inter-day 
RSD% 
(n=5) 
   
 0.023 94 5.2 4.8 5.4 
Pyr 2.5 5.7-51.1 0.027 0.114 102 4.6 6.8 7.4 
  
51.1-214.8  0.227 94 4.4 5.7 6.9 
   
 0.022 94 4.0 3.6 4.4 
LA 1.9 5.5-210.0 0.026 0.111 94 3.8 6.7 7.4 
       0.222 96 4.0 7.5 8.7 
   
 0.033 83 7.4 2.2 2.9 
AA 3.8 8.3-315.0 0.039 0.167 84 6.9 4.7 5.6 
       0.333 87 6.4 3.3 4.3 
   
 0.017 91 5.9 6.2 7.2 
SA 1.3 4.2-160.2 0.020 0.085 96 5.6 8.3 9.4 
       0.169 94 5.5 7.2 8.1 
   
 0.027 92 6.9 3.5 4.1 
PA 0.7 2.7-255.4 0.013 0.135 96 6.3 6.3 7.0 
       0.270 105 4.2 6.9 6.8 
   
 0.023 96 4.4 2.4 3.0 
BA 0.5 2.3-214.8 0.011 0.114 102 3.9 2.7 3.1 
       0.227 102 3.6 2.6 3.3 
   
 0.023 95 8.7 3.2 3.4 
iBA 0.6 2.3-214.8 0.011 0.114 94 6.3 3.5 3.6 
       0.227 100 5.2 3.4 3.8 
   
 0.020 95 3.2 5.1 5.8 
iVA 0.5 1.9-185.3 0.009 0.098 102 3.5 4.9 5.7 
       0.196 94 3.1 5.7 6.1 
   
 0.020 95 3.6 4.3 4.5 
VA 0.4 1.9-185.3 0.009 0.098 92 3.5 4.6 4.1 
       0.196 102 3.3 4.7 4.4 
         
aµMolar, b(µmoles/100mg) 480 
The mean value and %RSD were calculated from four measurements. The faecal sample 481 
initially contains 0.03, 0.07, 1.31, 0.04, 0.12, 0.81, 0.27, 0.23 and 0.21 µmoles/100mg of 482 
Pyr, LA, AA, SA, PA, BA, iBA, VA and iVA.  483 
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Table 3. Amount and relative percentage of the analytes detected in the human faecal 484 
samples (n=40) by UPLC-HR-MS method. 485 
 486 
Analyte 
µmoles / 100mg Relative % 
min max media s.d. media s.d. 
Pyr 0.02 0.04 0.03 0.01 0.5 0.3 
LA 0.00 0.37 0.07 0.07 1.2 1.8 
AA 0.71 10.10 4.24 2.12 48.0 12.2 
SA 0.10 1.30 0.21 0.19 2.9 2.0 
PA 0.22 5.41 1.70 1.15 18.5 7.0 
BA 0.11 4.60 1.20 1.03 11.4 6.7 
iBA 0.00 1.10 0.19 0.18 8.9 6.6 
iVA 0.20 1.10 0.37 0.19 4.6 2.0 
VA 0.10 3.60 1.16 0.85 4.1 2.5 
 487 
  488 
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Figure 1 489 
 490 
 491 
 492 
  493 
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Supplementary 1 494 
Molecular structures and product ions of possible interfering compounds. 495 
 496 
 497 
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Supplementary 2 499 
Statistical comparison of the results obtained by UHPLC-HR-MS with those provided by GC-FID 500 
and LC-UV method.  501 
 502 
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